SynthesisBMC cancer2024
High linc01116 expression may contribute to a poor prognosis in various cancers based on systematic reviews and meta-analyses.
Synthesis in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LINC01116 promotes nascent protein synthesis and cellular stemness through the miR-432-5p/FKBP7/14 regulatory axis in melanoma.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong non-coding RNA 01116 (linc01116) has been shown to be dysregulated in many tumors, and is closely related to the prognosis. This meta-analysis aimed to examine the correlation between linc01116 expression and cancer prognosis.
methodsSix electronic databases were searched, and eligible studies were screened based on the inclusion and exclusion criteria. Data including hazard ratios (HRs) and 95% confidence intervals (CIs), TNM stage, distant metastasis (DM) status, lymph node metastasis (LNM) status, and tumor size were extracted from the included studies. HRs and odds ratios (ORs) with their corresponding 95% CIs were separately pooled to assess the relationship between linc01116 expression and cancer prognosis. Sensitivity analysis and Begg's test were performed to assess publication or other biases.
resultsA total of 12 studies involving 809 patients were included in this meta-analysis. Analysis of pooled HRs with 95% CIs showed that high linc01116 expression was significantly correlated with poor overall survival (OS) (HR = 2.096; 95% CI: 1.555-2.638), progression-free survival (PFS) (HR, 1.9314; 95% CI: 1.020-3.657), disease-free survival (DFS) (HR = 2.067; 95% CI: 1.0889-3.9238), an advanced TNM stage (OR, 1.803; 95% CI: 1.270-2.562), and a poor histological grade (OR, 1.968; 95% CI: 1.288-3.007). However, no significant correlation was observed between linc01116 expression and LNM (OR, 1.198; 95% CI: 0.831-1.728), DM (OR, 1.114; 95% CI: 0.757-1.638), tumor size (OR, 1.336; 95% CI: 0.989-1.804), depth of invasion (OR, 1.375; 95% CI: 0.756-2.501), age (OR, 0.976; 95% CI: 0.742-1.283), or sex (OR, 0.810; 95% CI: 0.599-1.094). Sensitivity analysis indicated that the overall results of OS analysis were reliable and robust. In addition, Begg's test showed that none of the included studies had significant publication bias.
conclusionlinc01116 is upregulated in most cancers, and this upregulation is associated with a poor prognosis. Therefore, linc01116 serves as a promising therapeutic target and prognostic biomarker for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.